That is the best part about being on a GLP-1 medication, having that shut-off mechanism in your brain. Consumers are broadly supportive of changes to portion sizes, with 59 percent saying they would be more likely to visit restaurants that offer flexible, customizable, or innovative portion sizes, the Data Essential report found
Approved in November 2023, Zepbound is a dual agonist targeting both GLP-1 and GIP receptors
Try these weight loss strategies instead
It was put together with ease of implementation in mind
Hal Broxmeyer, Indiana University Bloomington, United States Updates Copyright 2019 Zhang, Chen, Zhong, Liu, Zheng and Gong
It is where we do follow up interviews when we have topics we're more interested in